Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study.
about
Lesinurad: what the nephrologist should know.The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies.Physiology of Hyperuricemia and Urate-Lowering Treatments.A meta-analysis of the efficacy of allopurinol in reducing the incidence of myocardial infarction following coronary artery bypass grafting.Association of Gout With Long-Term Cardiovascular Outcomes Among Patients With Obstructive Coronary Artery Disease
P2860
Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Multicentre, prospective, rand ...... otocol of the ALL-HEART study.
@en
Multicentre, prospective, rand ...... otocol of the ALL-HEART study.
@nl
type
label
Multicentre, prospective, rand ...... otocol of the ALL-HEART study.
@en
Multicentre, prospective, rand ...... otocol of the ALL-HEART study.
@nl
prefLabel
Multicentre, prospective, rand ...... otocol of the ALL-HEART study.
@en
Multicentre, prospective, rand ...... otocol of the ALL-HEART study.
@nl
P2093
P2860
P50
P1433
P1476
Multicentre, prospective, rand ...... rotocol of the ALL-HEART study
@en
P2093
ALL-HEART study group
Allan D Struthers
Andrew Walker
P2860
P304
P356
10.1136/BMJOPEN-2016-013774
P577
2016-09-08T00:00:00Z